P Capital acquired Avia Pharma, effectively doubling Avia’s size through the addition of three established pharmaceutical brands: Allergika in Germany, Decem in Finland, and Unimedic's Vitamin D portfolio. The deal is valued at $39 million, closed on August 12, 2022.
| Acquirer | P Capital (SE) |
|---|---|
| Target | Avia Pharma (SE) |
| Value ($M USD) | $39 |
| Type | Acquisition |
| Closed Date | 2022-08-12 |
| Announced Date | 2022-08-12 |
| Buy-side Advisors | Not disclosed |
| Sell-side Advisors | Not disclosed |
| Legal (buy) | Not disclosed |
| Legal (sell) | Not disclosed |
P Capital, a Swedish private equity firm, acquired Avia Pharma to strengthen its position as a leading Nordic specialty pharmaceutical platform. The $39 million deal effectively doubled the size of Avia through strategic acquisitions in Germany and Finland, significantly enhancing its portfolio of over-the-counter (OTC) brands.
Strategic Rationale
The acquisition is part of P Capital’s broader strategy to build a robust pharmaceutical platform with a focus on cash-generative OTC and specialty pharma products. Avia Pharma, founded in 2018, had already experienced significant growth through previous partnerships and strategic investments by P Capital.
With the addition of Allergika, Decem, and Unimedic’s Vitamin D portfolio, Avia Pharma expands its reach into multiple European markets while solidifying its position as a major player in specialty pharmaceuticals. The acquisition not only broadens Avia's geographical footprint but also increases its product diversity, setting the stage for further growth within the OTC market.
Financial Context
P Capital’s investment in Avia Pharma began four years ago and has resulted in a substantial increase in revenue, reflecting the firm's commitment to fostering long-term value creation through strategic partnerships. The acquisition of Allergika, Decem, and Unimedic's Vitamin D portfolio complements P Capital’s objective to establish Avia Pharma as a dominant player in Nordic specialty pharmaceuticals.
Avia Pharma’s success underscores the growing importance of OTC brands within the pharmaceutical industry, particularly those focused on health trends such as immune support and vitamin supplementation. With this acquisition, P Capital aims to capitalize on these market dynamics by expanding Avia's product range and operational capabilities across various European regions.
Outlook
The deal signals a new phase of growth for both P Capital and Avia Pharma, positioning them to capture opportunities in the evolving pharmaceutical landscape. As Avia integrates its newly acquired businesses, it is expected to further enhance its market position through continued innovation and strategic expansion.